In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claim 11 as follows:

1-10. (canceled).

11. (currently amended) A method for the treatment of metabolic syndrome in a human, whereby a pharmaceutically and pharmacologically effective amount of an angiotensin II type 1 receptor antagonist as the only active ingredient is administered to the human in need of such treatment wherein the angiotensin II type 1 receptor antagonist is of the general formula I:



I

wherein A is



I:3



I:4



I:5



I:6



I:7



I:8



I:10

or



I:11

or a pharmaceutically acceptable salt, solvate or stereochemical isomer thereof, or a solvate of such a salt; wherein the human with metabolic syndrome has a fasting plasma glucose above 6.1 mmol/L, a blood pressure above 140/90 mm Hg, and one or more of the following: a) plasma triglycerides above 1.7 mmol/L; b) HDL below 0.9 mmol/L (men) or 1.0 mmol/L (women); and c) body mass index above 30 kg/m^2.

12-13. (canceled).

14. (withdrawn) The method of claim 12, wherein A is I:13.

15. (withdrawn) The method of any one of claims 11-14, wherein the metabolically neutral antihypertensive substance is a calcium antagonist.

16. (withdrawn) The method of claim 15, wherein the metabolically neutral antihypertensive substance is selected from amlodipine, verapamil, nifedipine, nimodipine, diltiazem, nicardipine, felodipine, emlodipine, ryosidine, lacidipine, niguldipine, niludipine, nisoldipine, nitrendipine, nivaldipine, isradipine, flunarizine, diltiazem, mibefradil, prenylamine, fendiline, gallopamil, verapamil, tiapamil and anipamil, or a pharmaceutically acceptable salt thereof.

17. (previously presented) The method of claim 11, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.01 mg to about 1000 mg.

18. (previously presented) The method of claim 17, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to 750 mg.

19. (previously presented) The method of claim 18, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 1 mg to 500 mg.

20. (previously presented) The method of claim 11, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to about 300 mg per day.

21. (withdrawn) A method for the treatment of metabolic syndrome, whereby a pharmaceutically and pharmacologically effective amount of an angiotensin II type 1 receptor antagonist as the only active ingredient is administered to a subject in need of such treatment wherein the angiotensin II type 1 receptor antagonist is of the general formula I:



I

wherein A is



I:3



I:6



I:7



I:8



I:10

or



I:11

or a pharmaceutically acceptable salt, solvate or stereochemical isomer thereof, or a solvate of such a salt.

22. (withdrawn) The method of claim 21, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.01 mg to about 1000 mg.

23. (withdrawn) The method of claim 22, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to 750 mg.

24. (withdrawn) The method of claim 23, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 1 mg to 500 mg.

25. (withdrawn) The method of claim 21, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to about 300 mg per day.